Your trusted destination for CME, CPD & Medical Education across the Middle East.
Almoosa Specialist Hospital, Saudi Arabia
Dr. Ahmed Mohammad Alwabari is a Saudi medical oncologist and hematologist with more than a decade of experience in cancer care. He is particularly involved in breast oncology and thoracic oncology, and has participated as a speaker, moderator, and expert panelist at major oncology and breast-cancer meetings in Saudi Arabia and internationally. A recent Saudi breast-cancer consensus publication identifies him as a Medical Oncology Consultant at Almoosa Specialist Hospital in Dammam, Saudi Arabia.
Dr. Alwabari earned his MBBS from King Faisal University, Dammam, Saudi Arabia, in 2002. He subsequently moved to the United States for postgraduate medical training. He completed his Internal Medicine residency at Franklin Square Hospital Center in Baltimore, Maryland, in 2011, followed by fellowship training in Hematology and Oncology at the University of Arkansas for Medical Sciences (UAMS), Little Rock, completing his fellowship in 2014.
He is described as American-board-certified in Internal Medicine, Medical Oncology, and Hematology. His international training has provided him with experience in both general hematology/oncology and subspecialized cancer treatment.
Dr. Alwabari is a Consultant in Medical Oncology and Hematology at Almoosa Specialist Hospital, Saudi Arabia. Almoosa Health Group's official oncology service lists him as Dr. Ahmad Alwabari, Oncology and Hematology Consultant, based at its Al Aziziyah Center in Al Khobar.
He has also been described as holding an academic appointment as a Clinical Assistant Professor at the University of Arkansas for Medical Sciences (UAMS).
His principal areas of clinical interest include:
His involvement in breast cancer is particularly well documented. In 2024, he served as a moderator for the ESMO Advanced Course on CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer in Jeddah. The programme specifically lists him as moderator of the session covering biomarkers and clinical/pathological features of response to CDK4/6 inhibitors.
Dr. Alwabari has contributed to the Saudi oncology community through participation in scientific conferences, expert discussions, and clinical consensus activities. In the Saudi Arabia consensus statement on the management of early and metastatic breast cancer, he participated as a panelist in the online survey used to develop the expert recommendations. The publication identifies him as a medical oncology consultant at Almousa Hospital, Dammam.
He has also been involved in Saudi Oncology Society activities. At the 10th Annual Saudi Oncology Society Conference in 2023, he delivered a presentation on new advances in the treatment of HER2-positive metastatic breast cancer.
Some documented examples of his professional conference involvement include:
ESMO Advanced Course – Jeddah, 2024
He served as a moderator at the ESMO Advanced Course focusing on CDK4/6 inhibitors in hormone-receptor-positive/HER2-negative breast cancer.
10th Annual Saudi Oncology Society Conference – 2023
He presented on new advances in the treatment of HER2-positive metastatic breast cancer during the breast-cancer systemic-treatment session.
Success in Oncology Conference 2026
He is listed among the faculty of the Success in Oncology Conference (GSOC) in Saudi Arabia, with his profile identifying him as an American-board-certified medical oncologist and hematologist.
Dr. Alwabari has participated in clinical and academic oncology work, including the Saudi expert consensus process on breast cancer. His contribution to the consensus work is particularly relevant to his specialization because the publication addresses systemic management of early and metastatic breast cancer, including contemporary treatment strategies.
